University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Avista Therapeutics

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

OphthalmologyNeuroscience

Funding Stage

Seed

Founders

Leah ByrneJosé-Alain SahelPaul Sieving

Website

https://www.avistatx.com/
Avista Therapeutics

Avista Therapeutics is developing technologies to help gene medicines reach the cells where they are needed. Its Artemis platform combines artificial intelligence with insights into viral capsid biology and protein design to engineer delivery vectors, while its broader innovation platform tackles challenges in gene delivery and manufacturing. [1]

Founded by Leah Byrne, José-Alain Sahel and Paul Sieving, Avista builds on University of Pittsburgh research into retinal gene therapy. The company’s pipeline spans ophthalmology and central nervous system programs. UPMC Enterprises provided $10 million in seed funding, and a partnership with Roche supports the development of new AAV vectors for eye disease. [2] [3] [4]

Discover More with AI